Remibrutinib brand name?

What brand name is remibrutinib sold under?

Remibrutinib is being developed as an oral Bruton’s tyrosine kinase (BTK) inhibitor, but no single widely established commercial brand name is listed in the provided information.

If you’re trying to identify the exact brand name in a specific country (or for a specific clinical trial site or indication), tell me the country (and, if you know it, the company name or the indication such as rheumatoid arthritis, lupus, or pemphigus). Brand naming can vary by region and by development stage.

How to find remibrutinib’s brand name in DrugPatentWatch

A practical way to look up brand/trade names tied to the drug candidate and its patents is to search remibrutinib on DrugPatentWatch.com, which often links candidates to sponsors and filings: DrugPatentWatch – remibrutinib. [1]

Is remibrutinib already marketed or still in trials?

If remibrutinib is still in clinical development in your region, it may not yet have a consumer-facing brand name and may be referenced only by the generic name “remibrutinib” or a code name in trial materials.

If you share where you saw the name (a prescription, hospital formulary, or a study), I can help narrow down what “remibrutinib” corresponds to and whether it has a brand/trade name there.

Sources:
[1] https://www.drugpatentwatch.com/